skip to Main Content

“There has never been a greater need for clinical trials of new therapies in lymphoma. I am therefore delighted that ACT’s commitment to fund the TAP and IMPACT networks will increase trial capacity in the UK and at the same time permit the delivery of registration enabling trials by UK clinicians. Our patients will benefit from such innovation”

Dr Kate Cwynarski
Consultant Haematologist and Clinical Lead Lymphoma at UCLH